A prospective study of high dose sedation for rapid tranquilisation of acute behavioural disturbance in an acute mental health unit

BMC Psychiatry

Geoffrey K Isbister¹  Vincent Drinkwater²  Leonie Calver¹ 

[1] Department of Clinical Toxicology and Pharmacology, Calvary Mater Edith St, Waratah, Newcastle, NSW, Australia;Hunter New England Mental Health Centre, Psychiatric Emergency Services, Newcastle, Australia

关键词: Antipsychotic;    Benzodiazepine;    Droperidol;    Acute psychiatric unit;    Sedation;    Violence;   

Others  :  1123968
DOI  :  10.1186/1471-244X-13-225

 received in 2013-02-13, accepted in 2013-09-11,  发布年份 2013

【 摘 要 】

Background

Acute behavioural disturbance (ABD) is a common problem in psychiatry and both physical restraint and involuntary parenteral sedation are often required to control patients. Although guidelines are available, clinical practice is often guided by experience and there is little agreement on which drugs should be first-line treatment for rapid tranquilisation. This study aimed to investigate sedation for ABD in an acute mental healthcare unit, including the effectiveness and safety of high dose sedation.

Methods

A prospective study of parenteral sedation for ABD in mental health patients was conducted from July 2010 to June 2011. Drug administration (type, dose, additional doses), time to sedation, vital signs and adverse effects were recorded. High dose parenteral sedation was defined as greater than the equivalent of 10 mg midazolam, droperidol or haloperidol (alone or in combination), compared to patients receiving 10 mg or less (normal dose). Effective sedation was defined as a fall in the sedation assessment tool score by two or a score of zero or less. Outcomes included frequency of adverse drug effects, time to sedation/tranquilisation and use of additional sedation.

Results

Parenteral sedation was given in 171 cases. A single drug was given in 96 (56%), including droperidol (74), midazolam (19) and haloperidol (3). Effective sedation occurred in 157 patients (92%), and the median time to sedation was 20 min (Range: 5 to 100 min). The median time to sedation for 93 patients receiving high dose sedation was 20 min (5-90 min) compared to 20 min (5-100 min; p = 0.92) for 78 patients receiving normal dose sedation. Adverse effects occurred in 16 patients (9%); hypotension (14), oxygen desaturation (1), hypotension and oxygen desaturation (1). There were more adverse effects in the high dose sedation group compared to the normal dose group [11/93 (12%) vs. 5/78 (6%); p = 0.3]. Additional sedation was given in 9 of 171 patients (5%), seven in the high dose and two in the normal dose groups.

Conclusions

Large initial doses of sedative drugs were used for ABD in just over half of cases and additional sedation was uncommon. High dose sedation did not result in more rapid or effective sedation but was associated with more adverse effects.

【 授权许可】

   
2013 Calver et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]National Institute of Clinical Excellence: Violence: The short term management of distiurbed/violent Behaviourin the Psychiatric. In Patient Settings and the Emergency Departments. London: Clinical Guideline; 2005.
• [2]Cornaggia CM, Beghi M, Pavone F, Barale F: Aggression in psychiatry wards: a systematic review. Psychiatry Res 2011, 189(1):10-20.
• [3]Stubbs B: Physical injuries from restrictive interventions. Psychiatr Serv 2009, 60(3):406.
• [4]Allen MH, Currier GW, Hughes DH, Reyes Harde M, Docherty JP: The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med 2001, (Spec No):1-88. quiz 89-90
• [5]Brown S, Chhina N, Dye S: Use of psychotropic medication in seven English psychiatric intensive care units. The Psychiatrist 2010, 34:130-135.
• [6]Allen MH, Currier GW, Carpenter D, Ross R, Docherty JP: The Expert Consensus Guideline Series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 2005, 11:5-112.
• [7]Currier GW, Trenton A: Pharmacological treatment of psychotic agitation. CNS Drugs 2002, 16(4):219-228.
• [8]Brattaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, Dubin W, McGlynn C, Goodman L: Haliperidol, Lorazepam, or both for Psychotic Agitation? A Multiceter,Prospective, Double-Blind, Emergency Department Study. Am J Emerg Med 1997, 15:4.
• [9]Mental Health Drug and Alcohol Office: Mental Health for Emergency Departments-A Reference Guide. Sydney: NSW Department of Health; 2009.
• [10]British Medical Association and the Royal Pharmaceutical Society of Great Britain: British National Formulary. London; 2001.
• [11]Mantovani C, Migon MN, Alheira FV, Del-Ben CM: Management of the violent or agitated patient. Rev Bras Psiquiatr 2010, 32(Suppl 2):S96-103.
• [12]Chakrabarti A, Whicher E, Morrison M, Douglas-Hall P: 'As required' medication regimens for seriously mentally ill people in hospital. Cochrane Database Syst Rev 2007., 3CD003441
• [13]Calver LA, Stokes B, Isbister GK: Sedation assessment tool to score acute behavioural disturbance in the emergency department. Emerg Med Australas 2011, 23(6):732-740.
• [14]Isbister GK, Calver LA, Page CB, Stokes B, Bryant JL, Downes MA: Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Ann Emerg Med 2010, 56(4)):392-401. e391
• [15]Calver L, Downes M, Page C, Bryant J, Isbister G: The impact of a standardised intramuscular sedation protocol for acute behavioural disturbance in the emergency department. BMC Emerg Med 2010, 10(1):14. BioMed Central Full Text
• [16]Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, et al.: A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001, 21(4):389-397.
• [17]Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, et al.: A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002, 59(5):441-448.
• [18]Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, Feldman PD, Mintzer JE, Beckett LM, Breier A: Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002, 26(4):494-504.
• [19]Resnick M, Burton BT: Droperidol vs. haloperidol in the initial management of acutely agitated patients. J Clin Psychiatry 1984, 45(7):298-299.
• [20]Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I, Pickard A, Taylor CC, Roth J, et al.: Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry 2003, 48(11):716-721.
• [21]Lesem MD, Tran Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, Spyker DA, Kehne JH, Cassella V: Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 2011, 198:51-58.
• [22]Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, Saunders JC, Krueger J, Bradley P, San L, et al.: Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001, 158(7):1149-1151.
• [23]Binder RL EMD: Contemporary practices in managing acute violent patients in 20 psychiatric emergency rooms. Psychiatr Serv 1999, 50(12):1553-1554.
• [24]Martel ML: Ziprasidone for sedation of the agitated ED patient. Am J Emerg Med 2004, 22(3):238.